It remains to be determined if the sites involved in the binding of DAF and FcRn to E30 can inhibit TRIO-RhoA signaling, if drugs and vaccines can be developed to prevent or treat AML in neonates, and if a broad spectrum of antiviral drugs or combination vaccines for other diseases can be developed based on FcRn characteristics. The gene discussed is RHOA; the disease is acute myeloid leukemia.